The United States filed the complaint on July 13, 2026. The action concerns Edwards LifeSciences’ acquisition of JC Medical from Genesis MedTech Group and was brought at the request of the Federal Trade Commission.

Alongside the complaint, the government published a proposed final judgment and a competitive-impact statement. The proposed resolution seeks monetary relief and other remedies in connection with the transaction.

What the government alleges

The central issue is whether the acquisition was subject to reporting requirements under the Hart-Scott-Rodino Act. The government alleges that the transaction was reportable under the law but was structured to avoid filing.

That allegation places the case at the intersection of merger enforcement and the federal reporting system for transactions covered by the act. The proceeding is not presented simply as a dispute over whether the acquisition could affect competition. It also addresses the government’s claim that the parties did not comply with a required reporting obligation.

The complaint concerns a transaction involving JC Medical, Edwards LifeSciences and Genesis MedTech Group. The proposed judgment and competitive-impact statement set out the government’s position on the alleged reporting violation and the remedies it is seeking.

The allegations have not been established as a final finding. The filing describes the government’s claims, while the proposed judgment presents a resolution for consideration rather than a final court ruling.

Proposed monetary and other relief

The government is seeking monetary relief as well as additional remedies. The proposed final judgment is accompanied by a competitive-impact statement, which places the proposed resolution and its competition-related rationale in the Federal Register.

The notice does not establish the final amount of any civil penalty. That means the government’s request for monetary relief should not be treated as a completed penalty or as a final financial obligation imposed by a court.

The filing also does not announce a permanent block of the acquisition. The legal action instead puts the government’s allegations and proposed remedies before the court for review.

That distinction is important for the companies involved. A proposed judgment can describe the relief the government wants, but the outcome depends on the court’s consideration and any final judgment that may follow. Until then, the requested penalties and other remedies remain subject to the legal process.

What happens next

The matter remains subject to court consideration and the applicable public-comment process. Those steps are part of the review of the proposed final judgment before final court action.

The Federal Register publication is identified as 91 FR 46455. It includes the complaint-related notice, the proposed final judgment and the competitive-impact statement, placing the dispute in the public record as a federal antitrust matter.

For Edwards LifeSciences and Genesis MedTech, the immediate issue is the government’s request for monetary and other relief tied to the JC Medical acquisition. For JC Medical, the transaction is at the center of a federal proceeding focused on whether the acquisition should have been reported under the Hart-Scott-Rodino Act.

For federal enforcement agencies, the case illustrates the consequences the government is seeking when it alleges that a reportable transaction was structured to avoid filing. The proceeding also gives the court an opportunity to assess the proposed resolution and the remedies connected to the government’s claims.

The next decisive step is not a completed penalty or a final decision on the transaction’s status. It is the review of the proposed judgment through the court process and applicable public comments. The final outcome will depend on that review and any order entered by the court.

The FDA’s medical-device recall and early-alert page lists one Boston Scientific percutaneous-catheter issue dated July 24, 2026. The listing identifies the matter as an early alert rather than a completed recall classification.

What the FDA has identified

The available FDA entry identifies the company as Boston Scientific and the device category as a percutaneous catheter. It does not provide the product model, lot numbers, number of devices involved or a description of the failure mode.

The listing also does not state that the device caused injuries or deaths. No adverse-event finding is included in the approved information for the alert, and the available entry does not say how many devices may be affected.

The alert applies to medical devices distributed in the United States and appears in the FDA’s national system for medical-device recalls and early alerts. That system is intended to identify potentially serious corrections and recalls for healthcare providers and patients.

Why the classification matters

An early alert is not the same as a final recall determination. FDA guidance distinguishes early alerts from corrections and formal recalls, which are actions used to remove or correct devices that may violate safety requirements.

For this Boston Scientific device, the FDA has not identified the alert as a completed Class I recall in the available listing. Class I status therefore should not be inferred from the fact that the agency has opened an early alert.

The distinction is important because the alert indicates an active federal review, but it does not yet establish the full scope of the problem or the corrective action that may follow. The current record signals a potential patient-safety issue involving an invasive medical device while the agency gathers more information.

What remains unknown

The FDA listing available for this report does not identify the specific catheter model or the lots that may be involved. It also does not describe what went wrong, how many products were distributed, whether any patients were harmed or what steps Boston Scientific may be taking.

The available information likewise does not establish whether the issue affects every device in the broader percutaneous-catheter category. The agency’s listing names one Boston Scientific issue, but additional scope and distribution details require review of the underlying FDA communication.

Those omissions limit what patients, providers and other readers can conclude from the early alert alone. The notice confirms that FDA is examining the issue; it does not, by itself, provide a final assessment of risk or a completed recall order.

What happens next

The FDA says it is collecting information. The next known step is therefore continued review of the device issue and the underlying communication, including the details needed to determine its scope, risk and any appropriate corrective action.

Until that information is released, the approved FDA entry does not support identifying a specific affected model, lot, injury count or recall status beyond the early-alert designation dated July 24, 2026. Any later FDA update would be needed to establish whether the agency changes the classification or announces a formal correction or recall.

The FDA added the Class I classification on July 17, 2026, and made minor formatting changes to its communication on July 31. Abiomed began the removal action on May 22 after identifying a higher-than-expected rate of complaints involving thrombus formation during prolonged use.

The recall applies to specified products used with the 10th-generation Impella CP with SmartAssist. It does not cover every Impella device or every commercially available Impella CP generation.

Which products are affected

The FDA lists these affected products:

• 14 Fr x 13 cm Low Profile Introducer Kit for Impella CP — product code 1000434
• 14 Fr x 25 cm Low Profile Introducer Kit for Impella CP — product code 1000435
• Impella CP Set with SmartAssist, 10th Generation — product code 1000413

The FDA notice also lists a 14 Fr x 13 cm and 25 cm Low Profile Introducer Kit for Japan under product code 1000542. Hospitals should compare product labels and inventory with the FDA and Abiomed notices rather than assume that all Impella products are included.

The introducer kit is intended to facilitate access to the vascular system for introduction and removal of the Impella CP with SmartAssist and related devices.

What can go wrong

The reported hazard is thrombus formation during prolonged use of the introducer. The FDA says a thrombus may disrupt blood flow near the access site or become dislodged during support, manipulation or removal. A dislodged thrombus could obstruct a peripheral blood vessel and cause ischemia requiring prompt clinical assessment and intervention.

In less common circumstances, the problem could progress to irreversible vascular occlusion and potential permanent impairment if it is not corrected. The FDA says the cause remains under investigation; the recall record does not establish a final manufacturing root cause.

As of May 15, 2026, Abiomed had reported three serious injuries and no deaths associated with the issue. Those figures are tied to that reporting date and could change as additional information is received.

What hospitals should do

The FDA says affected products should not be used. Facilities should review inventory, quarantine identified units and arrange returns through Sedgwick under Abiomed’s instructions.

Abiomed also instructed customers to notify personnel who manage, transport, store, stock or use the devices. If products were sent to another facility, the receiving facility should be contacted and provided with the company’s notice. The FDA’s recall database lists the action as open and classified.

What the Class I designation means

A Class I designation means the FDA believes continued use of the recalled products could cause serious injury or death. It does not mean that every affected device has malfunctioned or that every patient exposed to one was injured.

What patients should know

The recall is directed primarily at hospitals, clinicians and device-management personnel. Patients who are currently receiving or were recently treated with an Impella device should not assume that the recall applies to their device. The FDA says other commercially available generations of Impella CP are not involved.

Patients with questions should contact their treating clinician or the hospital that provided care rather than trying to identify or manage a device themselves.

What to watch next

Hospitals and clinicians should watch for updated FDA or Abiomed instructions, additional injury reports, a change in the recall’s open status and any final determination about the cause of the problem.

Sources

• FDA recall safety communication
• FDA CDRH recall database
• MassDevice reporting

The problem is a small tear in the cannula tubing above the skin. If that happens, insulin can leak outside the pod instead of being fully delivered. The FDA says people may notice wetness on the skin or adhesive, or smell insulin, but the issue may also go unnoticed. If insulin is not delivered properly, blood sugar can rise and, in severe cases, lead to diabetic ketoacidosis.

Insulet told affected customers to check the lot number on the pod tray lid, the box or the pod itself and discontinue use immediately if a pod is on the affected list. If the pod being worn is from an impacted lot, it should be changed right away. Replacement pods are available at no cost, and the FDA says users should not rely only on pod alerts to spot the problem.

The FDA says about 7 million pods are included in the correction, although roughly 60% have already been used or expired. The agency reported 24 serious injuries and no deaths as of May 20. In a separate SEC filing, Insulet said it expects up to $50 million in costs from the correction in 2026 and does not expect to change its 2026 guidance.

Sources

• FDA Early Alert: Insulet insulin pump issue
• Insulet SEC Form 8-K filed May 26, 2026